GSIAS
OTLK icon

Garden State Investment Advisory Services’s Outlook Therapeutics OTLK Stock Holding History

Garden State Investment Advisory Services’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-745
Closed -$5.87K – 266
2023
Q4 		$5.87K Hold
745
– – ﹤0.01% 233
2023
Q3 		$3.29K Hold
745
– – ﹤0.01% 219
2023
Q2 		$25.9K Buy
745
+45
+6% +$1.23K 0.01% 233
2023
Q1 		$15.3K Hold
700
– – 0.01% 223
2022
Q4 		$15.1K Buy
+700
New +$15.2K 0.01% 192

Other funds holding OTLK

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Garden State Investment Advisory Services's OTLK Position: Q1 2024 in Review

Garden State Investment Advisory Services sold out of Outlook Therapeutics (OTLK) in Q1 2024, closing a stake of 745 shares — an estimated $5.87K sold.

Garden State Investment Advisory Services first reported a position in OTLK in Q4 2022 and held it in 5 quarters. The position peaked at $25.9K in Q2 2023. 56 funds tracked by Wall St. Rank hold OTLK as of Q1 2024.

  • Garden State Investment Advisory Services reported no remaining Outlook Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Garden State Investment Advisory Services sold 745 Outlook Therapeutics shares in Q1 2024, an estimated $5.87K.
  • Garden State Investment Advisory Services first reported a position in Outlook Therapeutics in Q4 2022 and held it in 5 quarters.
  • Garden State Investment Advisory Services's Outlook Therapeutics position peaked at $25.9K in Q2 2023.
  • 56 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2024.

Based on Garden State Investment Advisory Services's 13F filing for Q1 2024, filed 14 May 2024.